The effect of ginsenoside Rg3 combined with chemotherapy on immune function in non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials.
The effect of ginsenoside Rg3 combined with chemotherapy on immune function in non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials.
复制标题
Ginsenoside RG3与化学疗法结合对非小细胞肺癌的免疫功能的影响：随机对照试验的系统评价和荟萃分析。
DOI：
10.1097/md.0000000000033463
复制
发表时间：
2023-04-07
期刊：
影响因子：
1.6
通讯作者：
中科院分区：
文献类型：
--
作者：
非小细胞肺癌（NSCLC）的发生发展与肿瘤宿主的免疫状态密切相关。肿瘤细胞引起的免疫抑制和化疗药物产生的毒副作用导致免疫功能下降，最终导致临床化疗失败。人参皂苷Rg3在临床上有增强患者免疫功能的积极作用。因此，我们筛选和评估了人参皂苷Rg3益处的证据质量，并进行了荟萃分析，以评估人参皂苷Rg3对改善非小细胞肺癌免疫功能的影响。本研究检索了PubMed、EMBASE、Cochrane Library、CNKI、唯普（VIP）、万方等数据库，检索时间均为建库至2023年1月。根据入选标准，共纳入12项试验，样本量为1008例。结果显示，与一线化疗相比，人参皂苷Rg3联合一线化疗能更好地提高CD3+ T淋巴细胞水平[平均差值(MD) = 4.72；95%置信区间（CI）： 3.92, 5.53；P < 0.00001]， CD4+ T淋巴细胞（MD = 4.93, 95% CI: 4.61, 5.26, P < 0.00001）， CD8+ T淋巴细胞（MD = 2.67, 95% CI: 0.93, 4.37, P = 0.003）， CD4+/CD8+ T淋巴细胞（MD = 0.20, 95% CI: 0.09, 0.32, P = 0.006），提高自然杀伤细胞活性（MD = 2.11, 95% CI: 0.58, 3.63, P = 0.006），恢复化疗引起的白细胞计数下降，提高患者临床疗效。本研究证实人参皂苷Rg3在改善非小细胞肺癌患者免疫功能方面具有一定的疗效优势。
The occurrence and development of non-small cell lung cancer (NSCLC) are closely related to the immune status of the tumor-host. The immunosuppression caused by tumor cells and toxic side effects produced by chemotherapeutic drugs results in a decrease in immune function, ultimately leading to the failure of clinical chemotherapy treatment. Ginsenoside Rg3 has been clinically reported to have positive effects in enhancing immune function in patients. Thus, we screened and evaluated the quality of the evidence regarding the benefits of ginsenoside Rg3 and conducted a meta-analysis to assess the impact on improving immune function in NSCLC. The PubMed, EMBASE, Cochrane Library, CNKI, Weipu (VIP), and Wanfang databases were searched in this study, all from the time of library construction to January 2023. In total,12 trials with a sample size of 1008 cases were included based on the eligible criteria. The results showed that compared with first-line chemotherapy alone, the combination of ginsenoside Rg3 and first-line chemotherapy could better improve level of the CD3+ T lymphocytes [mean difference (MD) = 4.72; 95% confidence intervals (CI): 3.92, 5.53; P < .00001], CD4+ T lymphocytes (MD = 4.93; 95% CI: 4.61, 5.26; P < .00001), CD8+ T lymphocytes (MD = 2.67; 95% CI: 0.93, 4.37; P = .003), CD4+/CD8+ T lymphocytes (MD = 0.20; 95% CI: 0.09, 0.32; P = .0006), increase the activity of nature killer cells (MD = 2.11; 95% CI: 0.58, 3.63; P = .007), recover the decline of the white blood cell count induced by chemotherapy, and improve the clinical efficacy for patients. This study confirmed that ginsenoside Rg3 has some efficacy advantages for improving immune function in patients with NSCLC.